<!doctype html>
<html lang="en">
<head>
  <meta charset="utf-8" />
  <meta name="viewport" content="width=device-width, initial-scale=1" />
  <title>About • MultiOmics Inc.</title>

  <!-- SEO -->
  <meta name="description" content="Learn about MultiOmics Inc., the company developing LiquidMammo™, a microRNA-based blood test designed to complement imaging for earlier breast cancer detection.">
  <meta name="keywords" content="MultiOmics, LiquidMammo, molecular diagnostics, microRNA, early detection, liquid biopsy, biotech">

  <!-- Stylesheet -->
  <link rel="stylesheet" href="assets/css/styles.css" />
  <link rel="icon" href="favicon.png" type="image/png" />
</head>

<body>

<!-- ======================================
     HEADER
======================================= -->
<header>
  <div class="container">
    <nav>

      <!-- Brand -->
      <div class="brand">
        <img src="assets/logos/liquidmammo-logo.png" alt="LiquidMammo logo">
        <strong>LiquidMammo™</strong>
      </div>

      <!-- Navigation -->
      <div class="nav-links">
        <a href="index.html">Home</a>
        <a href="how-it-works.html">How It Works</a>
        <a href="science.html">Science</a>
        <a href="evidence.html">Evidence</a>
        <a href="patients.html">Patients</a>
        <a href="clinicians.html">Clinicians</a>
        <a href="biobank.html">Biobank</a>
        <a href="pricing.html">Pricing</a>
        <a href="contact.html">Contact</a>
        <a href="privacy.html">Privacy</a>
      </div>

    </nav>
  </div>
</header>


<!-- ======================================
     HERO (CLEAN WHITE HERO)
======================================= -->
<section class="hero-tight">
  <div class="container grid-2">

    <div>
      <span class="eyebrow">About MultiOmics Inc.</span>
      <h1>Advancing earlier, more equitable breast cancer detection</h1>
      <p class="small">
        MultiOmics Inc. develops LiquidMammo™, a microRNA‑based liquid biopsy
        designed to complement imaging across diverse populations.
      </p>
    </div>

    <div>
      <img 
        src="assets/logos/multiomics-logo.png"
        alt="MultiOmics Inc. logo"
        style="max-width:280px; margin:auto; display:block;"
      >
    </div>

  </div>
</section>


<!-- ======================================
     WHO WE ARE
======================================= -->
<section class="section">
  <div class="container grid-3">

    <div class="card">
      <h3>Who we are</h3>
      <p class="small">
        MultiOmics Inc. is a molecular diagnostics company transforming
        circulating microRNA signals into practical tools for earlier disease
        detection. Our team spans molecular biology, biostatistics, clinical
        diagnostics, and population‑level screening research.
      </p>
    </div>

    <div class="card">
      <h3>Our mission</h3>
      <p class="small">
        We aim to improve breast cancer screening performance by complementing
        mammography with biologically driven signals — particularly in dense
        breast populations where imaging sensitivity limits early detection.
      </p>
    </div>

    <div class="card">
      <h3>Where we operate</h3>
      <p class="small">
        MultiOmics Inc. is headquartered in Washington, DC and operates from
        LabCentral in Cambridge, MA — a leading MIT‑adjacent innovation hub
        supporting biotech commercialization.
      </p>
    </div>

  </div>
</section>


<!-- ======================================
     SCIENCE & TECHNOLOGY
======================================= -->
<section class="panel-light section">
  <div class="container">

    <h2>The science behind LiquidMammo™</h2>

    <div class="grid-3">

      <div class="card">
        <h3>microRNA biology</h3>
        <p class="small">
          LiquidMammo analyzes dysregulation patterns in circulating microRNAs —
          small non‑coding RNA molecules associated with tumor biology — to detect
          early biological changes that may precede imaging findings.
        </p>
      </div>

      <div class="card">
        <h3>Multi‑marker panel</h3>
        <p class="small">
          The proprietary panel integrates multiple microRNA markers to improve
          robustness, reproducibility, and performance across heterogeneous
          populations.
        </p>
      </div>

      <div class="card">
        <h3>Clinical rationale</h3>
        <p class="small">
          By layering molecular information with imaging, clinicians can improve
          interpretive confidence and better support early decision‑making,
          especially in women with dense breast tissue.
        </p>
      </div>

    </div>

  </div>
</section>


<!-- ======================================
     TEAM & ADVISORS
======================================= -->
<section class="section">
  <div class="container">

    <h2>Leadership & scientific advisors</h2>

    <div class="grid-3">

      <div class="card">
        <h3>Founding team</h3>
        <p class="small">
          The founding team brings experience in molecular diagnostics, assay
          development, epidemiology, and biostatistics.
        </p>
      </div>

      <div class="card">
        <h3>Clinical advisors</h3>
        <p class="small">
          Breast imaging radiologists and oncology experts contribute guidance on
          screening, diagnostic interpretation, and clinical deployment.
        </p>
      </div>

      <div class="card">
        <h3>Academic collaborations</h3>
        <p class="small">
          MultiOmics collaborates with academic researchers to refine assay
          performance, validate clinical utility, and evaluate subgroup behavior
          across diverse populations.
        </p>
      </div>

    </div>

  </div>
</section>


<!-- ======================================
     IMPACT & OPPORTUNITY
======================================= -->
<section class="panel-light section">
  <div class="container grid-3">

    <div class="card">
      <h3>Impact for patients</h3>
      <p class="small">
        A non‑invasive complement to imaging that helps clarify equivocal results,
        reduce false positives, and support earlier detection in dense‑breast
        populations.
      </p>
    </div>

    <div class="card">
      <h3>Impact for clinicians</h3>
      <p class="small">
        Standardized molecular insights that integrate seamlessly into clinical
        workflows without additional procedures.
      </p>
    </div>

    <div class="card">
      <h3>Business opportunity</h3>
      <p class="small">
        The demand for liquid‑biopsy based early detection is growing. A scalable
        CLIA LDT pathway allows rapid iteration with real‑world data and payer‑
        aligned value.
      </p>
    </div>

  </div>
</section>


<!-- ======================================
     FOOTER
======================================= -->
<footer>
  <div class="container footer-grid">

    <div>
      <strong>LiquidMammo™</strong><br/>
      A test developed by MultiOmics Inc.
      <p class="footer-note">
        MultiOmics Inc. is headquartered in Washington, DC and operates out of
        LabCentral in Cambridge, MA (MIT innovation ecosystem).
      </p>
    </div>

    <div class="footer-logo">
      <img src="assets/logos/multiomics-logo.png" alt="MultiOmics Inc. logo">
      <div class="footer-note" style="line-height:1.2">
        Developed by<br/>MultiOmics Inc.
      </div>
    </div>

  </div>

  <div class="container footer-note" style="margin-top:20px;">
    © <script>document.write(new Date().getFullYear())</script> MultiOmics Inc. •
    <a href="privacy.html">Privacy & Compliance</a> •
    <a href="contact.html">Order / Kits</a>
  </div>
</footer>

</body>
</html>

